Agency Information Collection Activities; Proposed Collection; Comment Request; Revisions to Labeling Requirements for Blood and Blood Components, Including Source Plasma; Correction, 6566-6567 [2012-2827]
Download as PDF
6566
Federal Register / Vol. 77, No. 26 / Wednesday, February 8, 2012 / Notices
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
Number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
Final Tribal TANF Data Report ........................................................................
Tribal TANF Annual Report .............................................................................
Tribal TANF Reasonable Cause/Corrective ....................................................
66
66
66
4
1
1
451
40
60
119,064
2,640
3,960
Estimated Total Annual Burden Hours .....................................................
........................
........................
........................
125,664
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade, SW., Washington, DC
20447, Attn: ACF Reports Clearance
Officer. Email address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2012–2882 Filed 2–7–12; 8:45 am]
tkelley on DSK3SPTVN1PROD with NOTICES
BILLING CODE 4184–01–P
VerDate Mar<15>2010
14:54 Feb 07, 2012
Jkt 226001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Notice of Change in Application
Requirements
Administration on
Developmental Disabilities, ACF, HHS.
ACTION: Notification of change in
allocation notification procedures to
State Protection and Advocacy Systems
(P&As) for mandatory awards under the
Help America Vote Act (HAVA), Public
Law 107–252.
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Melvenia Wright, Program Specialist.
Telephone: (202) 690–5557. Email:
Melvenia.Wright@acf.hhs.gov.
Dated: February 2, 2012.
Sharon Lewis,
Commissioner, Administration on
Developmental Disabilities.
[FR Doc. 2012–2920 Filed 2–7–12; 8:45 am]
BILLING CODE 4184–38–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0827]
CFDA Number: 93.617.
Statutory Authority: Title II, Subtitle D,
Part 5, of HAVA 42 U.S.C. 15461–62; Section
102 of the Developmental Disabilities
Assistance and Bill of Rights Act of 2000 (DD
Act) (42 U.S.C. 15002); and Section 509 of
the Rehabilitation Act of 1973 as amended
(29 U.S.C. 794e)
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Revisions to
Labeling Requirements for Blood and
Blood Components, Including Source
Plasma; Correction
The Administration for
Children and Families (ACF),
Administration on Developmental
Disabilities (ADD) has modified the
application requirements for awards
made to P&As under HAVA, Public Law
107–252. Under the program, formula
grants are allotted to States based on
population, financial need, and need for
service. P&As provide services to
individuals with developmental
disabilities based on the identification
of goals in the areas of emphasis listed
in the DD Act and based on public
input.
Section 291 of HAVA does not outline
specific application requirements for
P&As. Therefore, ADD has the
discretion to alter the process by which
P&As are notified of their annual
allocations. Accordingly, P&As will no
longer be required to submit an
application; and, an annual Funding
Opportunity Announcement (FOA) will
no longer be published. Instead, ADD
will now rely solely on the official
notification provided to P&As by ACF’s
Division of Mandatory Grants. This
notice informs P&As of the availability
of their annual award allocations.
AGENCY:
SUMMARY:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Food and Drug Administration,
HHS.
Notice; correction and extension
of comment period.
ACTION:
The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of December 30, 2011. In the
Federal Register of December 30, 2011,
FDA published a notice entitled
‘‘Agency Information Collection
Activities; Proposed Collection;
Comment Request; Revisions to
Labeling Requirements for Blood and
Blood Components, Including Source
Plasma,’’ which provided incorrect
publication information regarding the
availability of the final rule. This
document corrects this error and
extends the comment period. Elsewhere
in this issue of the Federal Register,
FDA is publishing a companion final
rule correction notice.
FOR FURTHER INFORMATION CONTACT:
Joyce Strong, Office of Policy, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 3208,
Silver Spring, MD 20993–0002, 301–
796–9148.
SUMMARY:
E:\FR\FM\08FEN1.SGM
08FEN1
Federal Register / Vol. 77, No. 26 / Wednesday, February 8, 2012 / Notices
In FR Doc.
2011–33555, appearing on page 82300
in the Federal Register of Friday,
December 30, 2011 (76 FR 82300), the
following corrections are made:
1. On page 82300, in the third
column, in the DATES section, the
submission date for comments should
be corrected to ‘‘April 9, 2012’’. We are
extending the comment period from
February 28, 2012, to 60 days after this
correction notice publishes to allow the
public sufficient time to comment.
2. On page 82301, in the first column,
in the second full paragraph in the
SUPPLEMENTARY INFORMATION section, the
last sentence is corrected to read: ‘‘This
document solicits comments on certain
labeling requirements for blood and
blood components, including Source
Plasma, finalized as part of a rule FDA
published on January 3, 2012, entitled
‘Revisions to Labeling Requirements for
Blood and Blood Components,
Including Source Plasma.’’’ We are
making this change because the final
rule inadvertently did not publish on
December 30, 2011.
SUPPLEMENTARY INFORMATION:
Dated: February 2, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012–2827 Filed 2–7–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
tkelley on DSK3SPTVN1PROD with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Endocrinologic
and Metabolic Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on March 28 and 29, 2012 from 8
a.m. to 5 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (rm.
1503), Silver Spring, MD 20993–0002.
Information regarding special
VerDate Mar<15>2010
14:54 Feb 07, 2012
Jkt 226001
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Paul Tran, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, (301)
796–9001, Fax: (301 ) 847–8533, email:
EMDAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1 (800)
741–8138 (301) 443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.
Agenda: On both days, the committee
will discuss the role of cardiovascular
assessment in the preapproval and
postapproval settings for drugs and
biologics developed for the treatment of
obesity.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 14, 2012.
Oral presentations from the public will
be scheduled between approximately
8:30 a.m. and 10 a.m. on March 29,
2012. Those individuals interested in
making formal oral presentations should
notify the contact person and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
6567
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before March 6, 2012. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 7, 2012.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Paul Tran at
least 7 days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 2, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2012–2760 Filed 2–7–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0067]
Assessment of Analgesic Treatment of
Chronic Pain—A Public Workshop;
Request for Comments
Food and Drug Administration.
Notice of public workshop;
request for comments.
AGENCY:
ACTION:
The Food and Drug Administration
(FDA), Center for Drug Evaluation and
Research (CDER), is announcing a
public workshop to hear a discussion of
the available data on the efficacy of
analgesics in the treatment of chronic
non-cancer pain (CNCP). The focus of
the presentations and discussions by
scientific experts and other stakeholder
E:\FR\FM\08FEN1.SGM
08FEN1
Agencies
[Federal Register Volume 77, Number 26 (Wednesday, February 8, 2012)]
[Notices]
[Pages 6566-6567]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-2827]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0827]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Revisions to Labeling Requirements for Blood and Blood
Components, Including Source Plasma; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction and extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register of December 30, 2011. In the
Federal Register of December 30, 2011, FDA published a notice entitled
``Agency Information Collection Activities; Proposed Collection;
Comment Request; Revisions to Labeling Requirements for Blood and Blood
Components, Including Source Plasma,'' which provided incorrect
publication information regarding the availability of the final rule.
This document corrects this error and extends the comment period.
Elsewhere in this issue of the Federal Register, FDA is publishing a
companion final rule correction notice.
FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3208,
Silver Spring, MD 20993-0002, 301-796-9148.
[[Page 6567]]
SUPPLEMENTARY INFORMATION: In FR Doc. 2011-33555, appearing on page
82300 in the Federal Register of Friday, December 30, 2011 (76 FR
82300), the following corrections are made:
1. On page 82300, in the third column, in the DATES section, the
submission date for comments should be corrected to ``April 9, 2012''.
We are extending the comment period from February 28, 2012, to 60 days
after this correction notice publishes to allow the public sufficient
time to comment.
2. On page 82301, in the first column, in the second full paragraph
in the SUPPLEMENTARY INFORMATION section, the last sentence is
corrected to read: ``This document solicits comments on certain
labeling requirements for blood and blood components, including Source
Plasma, finalized as part of a rule FDA published on January 3, 2012,
entitled `Revisions to Labeling Requirements for Blood and Blood
Components, Including Source Plasma.''' We are making this change
because the final rule inadvertently did not publish on December 30,
2011.
Dated: February 2, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-2827 Filed 2-7-12; 8:45 am]
BILLING CODE 4160-01-P